Omeros (OMER) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros (OMER) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 322.3% versus a gain of 16.7%. Rapport Therapeutics is the larger company by market cap ($1.45 billion vs $1.38 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OMER | RAPP |
|---|---|---|
| Share price | $19.01 | $30.13 |
| Market cap | $1.38B | $1.45B |
| 1-day change | +1.39% | -2.37% |
| YTD return | +9.14% | +1.71% |
| 1-year return | +322.30% | +16.72% |
| 5-year return | +142.56% | — |
| P/E ratio (TTM) | 15.58 | — |
| Forward P/E | 15.46 | — |
| EPS (TTM) | $1.22 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.24 | $52.93 |
| 52-week low | $4.06 | $23.75 |
| Distance from 52-week high | -10.50% | -43.08% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +44.66% | +109.23% |
| Average volume | 1.74M | 359.60K |
| Shares outstanding | 72.39M | 47.98M |
| Employees | 175 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed RAPP by 305.6 percentage points over the past year.
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
OMER vs RAPP FAQ
Which is bigger, Omeros or Rapport Therapeutics?
Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.45B compared with $1.38B for Omeros (OMER).
Which stock has performed better over the past year, OMER or RAPP?
OMER returned +322.30% over the past 12 months, compared with +16.72% for RAPP (price return, excluding dividends). Past performance does not predict future results.
Are Omeros and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.